Heidelberg Pharma Presents Promising Clinical Data for Lead ADC Candidate HDP-101

Heidelberg Pharma AG has disclosed new clinical data for its lead Amanitin-based Antibody Drug Conjugate (ADC) candidate, HDP-101, at the International Myeloma Society Annual Meeting in Rio de Janeiro. The data reveal the complete remission of one patient with relapsed or refractory multiple myeloma, following the 11th cycle of treatment.

During the ongoing Phase I/IIa clinical trial, several patients showed promising biological activity and objective improvement, indicating HDP-101's potential for addressing this high unmet medical need. Heidelberg Pharma will further discuss these results in an R&D webinar on 15 October 2024.

The webinar will feature insights from Heidelberg Pharma's management and key opinion leaders in the myeloma field, offering an opportunity for live questions from participants.